Abstract
Introduction:
The albuterol inhaler market in the United States will soon change from
low-value to significant. The only MDIs sold will be branded HFA formulations;
CFC propellants will be eliminated. Because the new HFA formulations are not
bioequivalent, companies will compete for market leadership by convincing
physicians and patients of their product' s superiority and by making strategic
pricing decisions.
Questions Answered in This Spectrum Report:
- The imminent discontinuation of many generic formulations of albuterol in
the United States will be the most signifi cant change in the respiratory
disease market in some time. Will today' s sales leaders weather the change
and continue to enjoy market dominance? How will the change affect generics
manufacturers? What marketing strategies will be key elements in development
of the market between 2006 and 2011? What are the market leaders doing now?
- As production of albuterol CFC ends, patients will have to switch from
familiar generics to more-expensive, branded HFA formulations that are not
interchangeable despite having the same active ingredient. How can
companies differentiate their products to win patient and physician
allegiance? How will higher costs affect patients and reimbursement providers?
How will they react?
- By the beginning of 2009, the U.S. market for inhaled albuterol MDIs will
comprise branded products exclusively. Which products will drive the market
at least until 2011? Which company is likely to own the biggest market share
in 2011? Which companies will lose market share? Are new companies with new
formulations likely to impact the market by 2011?
Scope
- Respiratory disease market: asthma and chronic obstructive
pulmonary disease prevalence and treatment; albuterol agents and manufacturers.
- Montreal Protocol: ban on CFC propellants; impact on the albuterol
market and on brand and generic manufacturers, consumers, and payers.
- From CFC to HFA: supply and demand challenges; manufacturer
compliance; non-bioequivalence of HFAs; reimbursement issues.
- Market outlook: continuing demand for albuterol products; DPI
formulations; pricing and product differentiation; U.S. market forecast;
winners and losers.
| 
View Cart
